<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1560-4071-2023-5540</article-id><article-id custom-type="edn" pub-id-type="custom">JTIUZW</article-id><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-5540</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОЦЕНКА РИСКА</subject></subj-group></article-categories><title-group><article-title>Магнитно-резонансная томография сердца в стратификации риска летальности пациентов с легочной артериальной гипертензией</article-title><trans-title-group xml:lang="en"><trans-title>Cardiac magnetic resonance imaging in mortality risk stratification of patients with pulmonary hypertension</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6954-7096</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гончарова</surname><given-names>Н. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Goncharova</surname><given-names>N. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гончарова Наталья Сергеевна — кандидат медицинских наук, старший научный сотрудник НИО "Некоронарогенные заболевания сердца"</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>St. Petersburg</p></bio><email xlink:type="simple">ns.goncharova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5226-1104</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рыжков</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ryzhkov</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Рыжков Антон Владимирович — заведующий отделением магнитно-резонансной томографии</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>St. Petersburg</p></bio><email xlink:type="simple">ryzhkov@almazovcentre.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7337-0972</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лапшин</surname><given-names>К. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Lapshin</surname><given-names>K. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лапшин Кирилл Борисович — заведующий отделением ОРИТ</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>St. Petersburg</p></bio><email xlink:type="simple">lapshinkb@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-6999-9136</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Котова</surname><given-names>А. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Kotova</surname><given-names>A. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Котова Анна Фаритовна — ординатор-кардиолог</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>St. Petersburg</p></bio><email xlink:type="simple">kotanfar@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7817-3847</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Моисеева</surname><given-names>О. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Moiseeva</surname><given-names>O. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Моисеева Ольга Михайловна — доктор медицинских наук, профессор, директор института Сердца и сосудов, заведующий НИО "Некоронарогенные заболевания сердца"</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>St. Petersburg</p></bio><email xlink:type="simple">moiseeva.cardio@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ НМИЦ им. В. А. Алмазова Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Almazov National Medical Research Center</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>26</day><month>08</month><year>2023</year></pub-date><volume>28</volume><issue>9</issue><fpage>5540</fpage><lpage>5540</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гончарова Н.С., Рыжков А.В., Лапшин К.Б., Котова А.Ф., Моисеева О.М., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Гончарова Н.С., Рыжков А.В., Лапшин К.Б., Котова А.Ф., Моисеева О.М.</copyright-holder><copyright-holder xml:lang="en">Goncharova N.S., Ryzhkov A.V., Lapshin K.B., Kotova A.F., Moiseeva O.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/5540">https://russjcardiol.elpub.ru/jour/article/view/5540</self-uri><abstract><sec><title>Цель</title><p>Цель. Провести сравнительную оценку показателей магнитно-резонансной томографии (МРТ) сердца с известными детерминантами прогноза у пациентов с легочной артериальной гипертензией (ЛАГ).</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В проспективное одноцентровое исследование включены 60 пациентов с ЛАГ в возрасте 21-72 года. В работе оценивались исходные показатели МРТ сердца, катетеризации правых камер сердца, эхокардиографии, уровень N-концевого промозгового натрийуретического пептида (NT-proBNP) и теста с 6-минутной ходьбой (Т6МХ).</p></sec><sec><title>Результаты</title><p>Результаты. Подтверждены достоверные корреляционные связи между инвазивными параметрами гемодинамики, NT-proBNP и показателями МРТ сердца. Отсутствовали достоверные корреляционные связи между сократительной способностью правого желудочка (ПЖ), объемом ПЖ и дистанцией в Т6МХ, функциональным классом (ФК) ЛАГ. Показатели МРТ сердца позволяли достоверно отделить пациентов низкого от пациентов промежуточного и высокого риска в соответствии со шкалой ESC/ERS 2015. По данным мультивариантного регрессионного анализа индекс конечного систолического объема ПЖ &gt;54 мл/м2 (отношение рисков 0,2; 95% доверительный интервал: 0,05-0,9; p=0,004) и 3-4 ФК ЛАГ (отношение рисков 0,2; 95% доверительный интервал: 0,07-0,8; p=0,026) оставались независимыми предикторами летальности.</p></sec><sec><title>Заключение</title><p>Заключение. Использование МРТ сердца у пациентов низкого риска может существенно улучшить раннее выявление дисфункции миокарда ПЖ и способствовать своевременной оптимизации ЛАГ-специфической терапии. В процессе наблюдения за пациентами с ЛАГ применение МРТ сердца потенциально может снизить потребность в повторных инвазивных исследованиях.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To compare cardiac magnetic resonance imaging (MRI) parameters with known prognosis determinants in patients with pulmonary hypertension (PH).</p></sec><sec><title>Material and methods</title><p>Material and methods. This prospective single-center study included 60 patients with PH aged 21-72 years. Cardiac MRI, right heart catheterization, echocardiography, N-terminal pro-brain natriuretic peptide (NT-proBNP) and 6-minute walk test (6MWT) were assessed at baseline.</p></sec><sec><title>Results</title><p>Results. Significant correlations between invasive hemodynamic parameters, NTproBNP and cardiac MRI parameters were confirmed. There were no significant correlations between the right ventricular (RV) contractility, RV volume and 6MWT distance, the functional class of PH. Cardiac MRI values allowed us to reliably separate patients at low risk from those at intermediate and high risk according to the 2015 ESC/ERS score. According to multivariate regression analysis, the right ventricular end systolic volume index &gt;54 ml/m2 (hazard ratio, 0,2; 95% confidence interval, 0,05-0,9; p=0,004) and class 3-4 PH (hazard ratio, 0,2; 95% confidence interval, 0,07-0,8; p=0,026) remained independent predictors of mortality.</p></sec><sec><title>Conclusion</title><p>Conclusion. The use of cardiac MRI in low-risk patients can significantly improve the early detection of right ventricular myocardial dysfunction and contribute to the timely optimization of PH-specific therapy. During monitoring patients with PH, cardiac MRI has the potential to reduce the need for repeated invasive investigations.</p></sec><sec><title> </title><p> </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>легочная артериальная гипертензия</kwd><kwd>магнитно-резонансная томография сердца</kwd><kwd>прогноз</kwd><kwd>стратификация риска.</kwd></kwd-group><kwd-group xml:lang="en"><kwd>pulmonary hypertension</kwd><kwd>cardiac magnetic resonance imaging</kwd><kwd>prognosis</kwd><kwd>risk stratification</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Грант РНФ, соглашение № 23-15-00-318</funding-statement><funding-statement xml:lang="en">Russian Science Foundation grant (agreement № 23-15-00-318)</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Galiè N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). European Heart Journal. 2016;37(1):67-119. doi:10.1093/eurheartj/ehv317.</mixed-citation><mixed-citation xml:lang="en">Galiè N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). European Heart Journal. 2016;37(1):67-119. doi:10.1093/eurheartj/ehv317.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Humbert M, Kovacs G, Hoeper M, et al. ESC/ERS Scientific Document Group (2022). 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The European respiratory journal. 2022;61(1). doi:10.1183/13993003.00879-2022.</mixed-citation><mixed-citation xml:lang="en">Humbert M, Kovacs G, Hoeper M, et al. ESC/ERS Scientific Document Group (2022). 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The European respiratory journal. 2022;61(1). doi:10.1183/13993003.00879-2022.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Hur DJ, Sugeng L. Non-invasive Multimodality Cardiovascular Imaging of the Right Heart and Pulmonary Circulation in Pulmonary Hypertension. Front Cardiovasc Med. 2019;14(6):24. doi:10.3389/fcvm.2019.00024.</mixed-citation><mixed-citation xml:lang="en">Hur DJ, Sugeng L. Non-invasive Multimodality Cardiovascular Imaging of the Right Heart and Pulmonary Circulation in Pulmonary Hypertension. Front Cardiovasc Med. 2019;14(6):24. doi:10.3389/fcvm.2019.00024.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Maceira AM, Prasad SK, Khan M, Pennell DJ. Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2006;8(3):417-26. doi:10.1080/10976640600572889.</mixed-citation><mixed-citation xml:lang="en">Maceira AM, Prasad SK, Khan M, Pennell DJ. Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2006;8(3):417-26. doi:10.1080/10976640600572889.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Maceira AM, Prasad SK, Khan M, Pennell DJ. Reference right ventricular systolic and diastolic function normalized to age, gender and body surface area from steady-state free precession cardiovascular magnetic resonance. Eur Heart J. 2006;27(23):2879-88. doi:10.1093/eurheartj/ehl336.</mixed-citation><mixed-citation xml:lang="en">Maceira AM, Prasad SK, Khan M, Pennell DJ. Reference right ventricular systolic and diastolic function normalized to age, gender and body surface area from steady-state free precession cardiovascular magnetic resonance. Eur Heart J. 2006;27(23):2879-88. doi:10.1093/eurheartj/ehl336.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Авдеев С. Н., Барбараш О. Л., Баутин А.Е. и др. Легочная гипертензия, в том числе хроническая тромбоэмболическая легочная гипертензия. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(12):4683. doi:10.15829/1560-4071-2021-4683.</mixed-citation><mixed-citation xml:lang="en">Avdeev SN, Barbarash OL, Bautin AE, et al. 2020 Clinical practice guidelines for Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. Russian Journal of Cardiology. 2021;26(12):4683. (In Russ.) doi:10.15829/1560-4071-2021-4683.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Hoeper MM, Pausch C, Olsson KM, et al. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. The European respiratory journal. 2022;60(1). doi:10.1183/13993003.02311-2021.</mixed-citation><mixed-citation xml:lang="en">Hoeper MM, Pausch C, Olsson KM, et al. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. The European respiratory journal. 2022;60(1). doi:10.1183/13993003.02311-2021.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">van de Veerdonk MC, Marcus JT, Westerhof N, et al. Signs of right ventricular deterioration in clinically stable patients with pulmonary arterial hypertension. Chest. 2015;147(4):1063- 71. doi:10.1378/chest.14-0701.</mixed-citation><mixed-citation xml:lang="en">van de Veerdonk MC, Marcus JT, Westerhof N, et al. Signs of right ventricular deterioration in clinically stable patients with pulmonary arterial hypertension. Chest. 2015;147(4):1063- 71. doi:10.1378/chest.14-0701.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Hendriks PM, van de Groep LD, Veen KM, et al. Prognostic value of brain natriuretic peptides in patients with pulmonary arterial hypertension: A systematic review and metaanalysis. American heart journal. 2022;250:34-44. doi:10.1016/j.ahj.2022.05.006.</mixed-citation><mixed-citation xml:lang="en">Hendriks PM, van de Groep LD, Veen KM, et al. Prognostic value of brain natriuretic peptides in patients with pulmonary arterial hypertension: A systematic review and metaanalysis. American heart journal. 2022;250:34-44. doi:10.1016/j.ahj.2022.05.006.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Alabed S, Shahin Y, Garg P, et al. Cardiac-MRI Predicts Clinical Worsening and Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. JACC. Cardiovascular imaging. 2021;14(5):931-42. doi:10.1016/j.jcmg.2020.08.013.</mixed-citation><mixed-citation xml:lang="en">Alabed S, Shahin Y, Garg P, et al. Cardiac-MRI Predicts Clinical Worsening and Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. JACC. Cardiovascular imaging. 2021;14(5):931-42. doi:10.1016/j.jcmg.2020.08.013.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Alandejani F, Hameed A, Tubman E, et al. Imaging and Risk Stratification in Pulmonary Arterial Hypertension: Time to Include Right Ventricular Assessment. Frontiers in cardiovascular medicine. 2022;9. doi:10.3389/fcvm.2022.797561.</mixed-citation><mixed-citation xml:lang="en">Alandejani F, Hameed A, Tubman E, et al. Imaging and Risk Stratification in Pulmonary Arterial Hypertension: Time to Include Right Ventricular Assessment. Frontiers in cardiovascular medicine. 2022;9. doi:10.3389/fcvm.2022.797561.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Y, Zhao S, Lu M. State-of-the-art cardiac magnetic resonance in pulmonary hypertension: An update on diagnosis, risk stratification and treatment. Trends in cardiovascular medicine. 2022;S1050-1738(22)00146-3. Advance online publication. doi:10.1016/j.tcm.2022.12.005.</mixed-citation><mixed-citation xml:lang="en">Wang Y, Zhao S, Lu M. State-of-the-art cardiac magnetic resonance in pulmonary hypertension: An update on diagnosis, risk stratification and treatment. Trends in cardiovascular medicine. 2022;S1050-1738(22)00146-3. Advance online publication. doi:10.1016/j.tcm.2022.12.005.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Vasquez M, Nagel E. Clinical indications for cardiovascular magnetic resonance. Heart (British Cardiac Society). 2019;105(22):1755-62. doi:10.1136/heartjnl-2018-312971.</mixed-citation><mixed-citation xml:lang="en">Vasquez M, Nagel E. Clinical indications for cardiovascular magnetic resonance. Heart (British Cardiac Society). 2019;105(22):1755-62. doi:10.1136/heartjnl-2018-312971.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Simpson CE, Kolb TM, Hsu S, et al. Ventricular mass discriminates pulmonary arterial hypertension as redefined at the Sixth World Symposium on Pulmonary Hypertension. Pulmonary circulation. 2022;12(1):e12005. doi:10.1002/pul2.12005.</mixed-citation><mixed-citation xml:lang="en">Simpson CE, Kolb TM, Hsu S, et al. Ventricular mass discriminates pulmonary arterial hypertension as redefined at the Sixth World Symposium on Pulmonary Hypertension. Pulmonary circulation. 2022;12(1):e12005. doi:10.1002/pul2.12005.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
